Oncotech Nordic

Oncotech collaborates with internationally renowned oncologists and clinical researchers in Europe, the Middle East, and Africa. The company's R&D focus is on diagnostics (mobile real-time cancer screening technology) and cancer treatment therapies. It has developed Ophtascan™, a mobile real-time detection system capable of detecting precancerous lesions as well as all four stages of lung cancer, cervical cancer, breast cancer, uterine cancer, and prostate cancer. Ophtascan™ can also be used to detect type 2 diabetes. Established in London, UK, in 2020, the company founded an operational subsidiary, Oncotech Nordic AB, in Northern Europe in 2021, led by CEO Andre Rafnsson. Oncotech currently has registered offices in the UAE and Qatar and is rapidly expanding in the Middle Eastern market.